Precis:

Patients with metastatic melanoma who are HLA-A201 positive and HIV and Hepatitis B negative and who have previously received the gp-209-2M peptide will be treated by the adoptive transfer of cloned peripheral blood lymphocytes or tumor infiltrating lymphocytes sensitized, in vitro, to the gp-209-2M peptide. This study will evaluate the toxicity, immunologic effects and potential therapeutic role of this treatment.